Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages
New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was associated with similar weight loss among women of different ages and at different life stages: before, during and after menopause.
A recent study, to be presented at the European Association for the Study of Diabetes meeting in Milan, Italy, reveals that the GLP-1 receptor agonist medication orforglipron, when taken daily, led to similar weight loss in women across different menopausal stages. Researcher Dr. Hunter Thomas Hoffman of Eli Lilly and Company, the drug's manufacturer, led the study alongside colleagues.
Obesogenic estrogen deficiency intensifies obesity during menopause, a chronic, progressive disease. Orforglipron, a small-molecule, nonpeptide GLP-1 receptor agonist, demonstrated significant body weight (BW) reductions in two studies: ATTAIN-1, which included obese and overweight individuals without diabetes, and ATTAIN-2, which encompassed those with both conditions.
Researchers evaluated orforglipron's impact on BW in women based on their menopausal stage: premenopausal, perimenopausal, or postmenopausal. The study analyzed 142 to 225 women in each category who had at least one weight-related medical condition. The findings showed that women receiving orforglipron experienced substantial weight loss (up to 14%) and waist circumference reductions (up to 12.5 cm or 4.9 inches) in all three menopausal stages, both in ATTAIN-1 and ATTAIN-2 studies.
Additionally, 83% of women treated with orforglipron achieved at least a 5% body weight reduction, compared to 30% of those given a placebo.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
